S&P 500   5,031.91 (-0.39%)
DOW   37,678.25 (-0.32%)
QQQ   429.40 (-0.39%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.91 (-0.39%)
DOW   37,678.25 (-0.32%)
QQQ   429.40 (-0.39%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.91 (-0.39%)
DOW   37,678.25 (-0.32%)
QQQ   429.40 (-0.39%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.91 (-0.39%)
DOW   37,678.25 (-0.32%)
QQQ   429.40 (-0.39%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

$14.09
-0.33 (-2.29%)
(As of 11:12 AM ET)
Today's Range
$14.06
$14.51
50-Day Range
$8.31
$20.32
52-Week Range
$7.58
$21.44
Volume
6,738 shs
Average Volume
45,541 shs
Market Capitalization
$181.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Greenwich LifeSciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
149.7% Upside
$36.00 Price Target
Short Interest
Healthy
2.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Greenwich LifeSciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$327,722 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars

Medical Sector

540th out of 930 stocks

Pharmaceutical Preparations Industry

253rd out of 433 stocks

GLSI stock logo

About Greenwich LifeSciences Stock (NASDAQ:GLSI)

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

GLSI Stock Price History

GLSI Stock News Headlines

A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023
This company has increased its dividend every year for 54 years
There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.
2 Rare Insider Buys in a Frothy Market
Greenwich: Closed pub reopens as community hub
See More Headlines
Receive GLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/17/2024
Next Earnings (Estimated)
5/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLSI
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.00
High Stock Price Target
$36.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+149.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.03 per share

Miscellaneous

Free Float
6,057,000
Market Cap
$185.30 million
Optionable
Not Optionable
Beta
1.37
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

GLSI Stock Analysis - Frequently Asked Questions

Should I buy or sell Greenwich LifeSciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLSI shares.
View GLSI analyst ratings
or view top-rated stocks.

What is Greenwich LifeSciences' stock price target for 2024?

1 Wall Street research analysts have issued twelve-month target prices for Greenwich LifeSciences' stock. Their GLSI share price targets range from $36.00 to $36.00. On average, they predict the company's stock price to reach $36.00 in the next year. This suggests a possible upside of 149.7% from the stock's current price.
View analysts price targets for GLSI
or view top-rated stocks among Wall Street analysts.

How have GLSI shares performed in 2024?

Greenwich LifeSciences' stock was trading at $10.52 on January 1st, 2024. Since then, GLSI stock has increased by 37.1% and is now trading at $14.42.
View the best growth stocks for 2024 here
.

When is Greenwich LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our GLSI earnings forecast
.

When did Greenwich LifeSciences IPO?

Greenwich LifeSciences (GLSI) raised $7 million in an IPO on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital served as the underwriter for the IPO.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLSI) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners